as 09-06-2024 4:00pm EST
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | SARASOTA |
Market Cap: | 9.8M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 1.3M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.02 | EPS Growth: | N/A |
52 Week Low/High: | $0.52 - $7.74 | Next Earning Date: | 08-09-2024 |
Revenue: | $7,466 | Revenue Growth: | -93.58% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
OGEN Breaking Stock News: Dive into OGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
MT Newswires
3 days ago
MT Newswires
3 days ago
GlobeNewswire
3 days ago
MT Newswires
17 days ago
GlobeNewswire
17 days ago
GlobeNewswire
22 days ago
GlobeNewswire
24 days ago
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.